The Role of Double Renin-Angiotensin System Blockade
DOI:
https://doi.org/10.2015/hc.v4i3.330Abstract
Blockade of the renin-angiotensin system (RAS) is now recognized as an effective means of lowering blood pressure and protecting hypertensive patients from end-organ damage. There are three pharmacologic approaches to blockade of the RAS, with angiotensin-converting enzyme (ACE) inhibitors, with angiotensin II receptor blockers (ARBs), and with direct renin inhibitors. Clinical studies with the first two classes have shown that neither one achieves complete blockade of the RAS. However, an almost complete blockade of the RAS can be achieved by combination of an ACE inhibitor plus an ARB, albeit not with consistent benefits. A complete blockade of the RAS can also be obtained by combination of an ARB with a renin inhibitor. Further outcome trials are needed to show which combination offers long-term advantages in terms of end-organ protection.
Downloads
Issue
Section
License
Authors who publish with this journal agree to the following terms:a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
